Loading clinical trials...

Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds | Clinical Trials | Clareo Health

TERMINATEDPHASE4

Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate

NCT04346667•Government of Punjab, Specialized Healthcare and Medical Education Department

View on ClinicalTrials.gov

Summary

To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.

Eligibility

Age

20 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Nasopharyngeal RT-PCR positive SARS-CoV-2 patient
•2. Age 20-50 years
•3. BMI 18-28 kg/m2
•4. Informed consent

Exclusion Criteria

•1. Symptoms: Cough, fever, shortness of breath
•2. O2 saturation by pulse-oximeter below 94%
•3. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes
•4. Arrhythmias and/or history of arrythmia
•5. Psoriasis and/or history of psoriasis
•6. Neuropathy or myopathy and/or history of these
•7. Hypoglycemia and/or history of hypoglycemia
•8. Pre-existing hepatic disease
•9. Pre-existing renal disease
•10. Use of antacids within 1 week
+3 more criteria

Locations (3)

Expo Covid Center

Lahore, Punjab Province, Pakistan

Mayo Hospital

Lahore, Punjab Province, Pakistan

Pakistan Kidney and Liver Institute

Lahore, Punjab Province, Pakistan

Key Dates

Start Date

April 14, 2020

Primary Completion Date

August 23, 2020

Completion Date

August 30, 2020

Last Updated

March 10, 2021

Enrollment

125

ACTUAL participants

Conditions

SARS-CoV-2Coronavirus InfectionAsymptomatic ConditionCOVID-19

Interventions

Hydroxychloroquine Sulfate Regular dose

DRUG

Hydroxychloroquine Sulfate Loading Dose

DRUG

Chloroquine

DRUG

Placebo

DRUG

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287

Long COVIDSars-CoV-2 Infection+2 more

View study

RECRUITINGPHASE1

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT05141058

SARS-CoV-2 Infection

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

Inclusion Criteria

Exclusion Criteria

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study